Abstract:Activation of the Nod-like receptor 3 (NLRP3) inflammasome is important for activation of innate immune responses, but improper and excessive activation can cause inflammatory disease. We previously showed that glycolysis, a metabolic pathway that converts glucose into pyruvate, is essential for NLRP3 inflammasome activation in macrophages. Here, we investigated the role of metabolic pathways downstream glycolysis – lactic acid fermentation and pyruvate oxidation—in activation of the NLRP3 inflammasome. Using pharmacological or genetic approaches, we show that decreasing lactic acid fermentation by inhibiting lactate dehydrogenase reduced caspase-1 activation and IL-1β maturation in response to various NLRP3 inflammasome agonists such as nigericin, ATP, monosodium urate (MSU) crystals, or alum, indicating that lactic acid fermentation is required for NLRP3 inflammasome activation. Inhibition of lactate dehydrogenase with GSK2837808A reduced lactate production and activity of the NLRP3 inflammasome regulator, phosphorylated protein kinase R (PKR), but did not reduce the common trigger of NLRP3 inflammasome, potassium efflux, or reactive oxygen species (ROS) production. By contrast, decreasing the activity of pyruvate oxidation by depletion of either mitochondrial pyruvate carrier 2 (MPC2) or pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1) enhanced NLRP3 inflammasome activation, suggesting that inhibition of mitochondrial pyruvate transport enhanced lactic acid fermentation. Moreover, treatment with GSK2837808A reduced MSU-mediated peritonitis in mice, a disease model used for studying the consequences of NLRP3 inflammasome activation. Our results suggest that lactic acid fermentation is important for NLRP3 inflammasome activation, while pyruvate oxidation is not. Thus, reprograming pyruvate metabolism in mitochondria and in the cytoplasm should be considered as a novel strategy for the treatment of NLRP3 inflammasome-associated diseases.

Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation

A role for mitochondria in NLRP3 inflammasome activation

A novel mechanism for NLRP3 inflammasome activation

Initiation and perpetuation of NLRP3 inflammasome activation and assembly

New mitochondrial DNA synthesis enables NLRP3 inflammasome activation

Hexokinase dissociation from mitochondria promotes oligomerization of VDAC that facilitates NLRP3 inflammasome assembly and activation

Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation

Mitochondrial dysfunction as a driver of NLRP3 inflammasome activation and its modulation through mitophagy for potential therapeutics

Mitochondrial damage activates the NLRP10 inflammasome

Niclosamide activates the NLRP3 inflammasome by intracellular acidification and mitochondrial inhibition

Cathepsin B Is Required for NLRP3 Inflammasome Activation in Macrophages, Through NLRP3 Interaction

Distinct changes in endosomal composition promote NLRP3 inflammasome activation

Mitochondrial calcium uniporter promotes phagocytosis-dependent activation of the NLRP3 inflammasome

IITZ-01 Activates NLRP3 Inflammasome by Inducing Mitochondrial Damage

CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation

Structural basis for the oligomerization-facilitated NLRP3 activation

Lipopolysaccharide promotes NLRP3 inflammasome activation by inhibiting TFEB-mediated autophagy in NRK-52E cells

The NLRP3 inflammasome: molecular activation and regulation to therapeutics

How location and cellular signaling combine to activate the NLRP3 inflammasome

LRRC8A is essential for hypotonicity-, but not for DAMP-induced NLRP3 inflammasome activation

Regulation of the NLRP3 inflammasome by autophagy and mitophagy